A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries
about
Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDSGetting to 90-90-90 targets for children and adolescents HIV in low and concentrated epidemics: bottlenecks, opportunities, and solutionsTrends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysisThe Global Health Impact Index: Promoting Global HealthPrices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisHIV-1 drug resistance and resistance testing.Viewpoint: Counterfeit medicines and substandard medicines: Different problems requiring different solutions.The 90 90 90 strategy to end the HIV Pandemic by 2030: Can the supply chain handle it?Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP).Recent developments in hiv treatment and their dissemination in poor countriesRapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis CDriving a decade of change: HIV/AIDS, patents and access to medicines for all.The first decade of antiretroviral therapy in Africa.HIV as a chronic disease considerations for service planning in resource-poor settings.Generic drugs: Review and experiences from South India.Assessing the population health impact of market interventions to improve access to antiretroviral treatment.Access to hepatitis C medicines.Ethical use of antiretroviral resources for HIV prevention in resource poor settings.Technology innovation for infectious diseases in the developing world.The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysisClinical oncology in resource-limited settingsConvergent innovation for sustainable economic growth and affordable universal health care: innovating the way we innovate.A Cost Analysis of the Jan Aushadhi Scheme in India.Estimated generic prices for novel treatments for drug-resistant tuberculosis.Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.Eliminating HIV & AIDS in India: A roadmap to zero new HIV infections, zero discrimination & zero AIDS-related deaths.World AIDS day 2013: "Getting to zero: ending AIDS".'Getting to zero': a steep path ahead.Indian pharmaceutical patent prosecution: The changing role of Section 3(d).Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.Improving health-care delivery in low-resource settings with nanotechnology: Challenges in multiple dimensions.Access to Medicines in Resource-limited Settings: The End of a Golden Decade?HIV—Medical PerspectiveThe reality behind the rhetoric: How European policies risk harming access to generic medicines in developing countriesPredictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania
P2860
Q27004509-122CBC33-63ED-43A4-9084-81DF438D9902Q28074763-FBB66E26-88E9-4634-AD0F-44589195A98BQ28478773-2CBE80B7-8A9F-4567-92C0-CA12691D2ECBQ28551476-D85FB61A-1C3F-4C8F-9077-AB89CC5C5FFCQ28552507-B1AF1F3E-EBBA-4566-9D8C-E35304EEF0CDQ30245693-2FA7AC85-BC25-4FDE-B2B3-F284C6865A92Q30376760-2E6166EB-05D3-421C-9BB8-FEB97CE332D7Q30390065-D0510903-DC94-42D1-8EEB-9D73DD008294Q33727955-F5182DA0-8622-4FF7-82CF-CDE958B8008FQ34400513-CA795BB1-8DF2-4276-B09E-73FF5ED0EEDFQ34536041-5C4FC7BA-BC58-42E2-824C-233B726522B6Q34808796-74559468-5B4C-4FFC-9408-CA1E965661B0Q35337985-A601FD6D-8943-47E9-93F5-9B818FD846F7Q35397167-35D3F15B-743A-4D4E-9F87-F9CE6DB69C9EQ35948976-1071AF70-1A3B-4E5F-88DB-AA1C8D706852Q36201249-14EC19D6-69C0-4229-88B9-10309794B765Q36211833-92CF8EAC-D9C0-409D-9D6F-49877E4B67FFQ36377733-C84C4F9E-1A87-4DF8-AE52-6684B3AF7E1CQ37008584-E6958CBC-8CCE-4C71-948B-46B457F7C4E0Q37207470-7D413666-3E8C-4121-8961-F7A889247283Q37365923-92F7EE70-E571-4A52-847C-F5C825BC8CBAQ38258056-9EFCFC0E-DCF6-406C-8429-C12D7E7C5615Q38622435-CE7D6C62-7D55-43C2-930A-F8AEF323BF2EQ40377338-75703C57-BBF8-4CB9-8E45-20D56676220CQ41926477-0F9E4520-03A6-417E-885C-7398576D2B96Q42350271-CFC5709B-16A7-49AA-88C9-392BA6C5780FQ42369075-7177F5A3-53B9-4879-9883-4962BC1DA903Q42655357-B7E7C9F5-3A62-491A-B0D3-4F250788F63FQ52613279-ADD56C7A-53BC-44BF-B798-930E9DC73FB9Q52659410-EAF2DA67-75CC-4182-88B8-8B05C38B2C06Q55345336-FCE54883-B2EC-4A02-A3E6-3ABC77C7CAA3Q56967553-2A522E4D-DD98-4024-B061-067557C6BE80Q58339113-0842B8DF-FD7A-4A00-8804-2C2B70DDDB39Q58593358-C8F2AAA1-7D7A-4B6D-9E01-ED2D780170E2Q58729902-D6ADFC45-48B9-49D8-B86C-52713B3109A7
P2860
A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A lifeline to treatment: the r ...... icines to developing countries
@ast
A lifeline to treatment: the r ...... icines to developing countries
@en
A lifeline to treatment: the r ...... icines to developing countries
@nl
type
label
A lifeline to treatment: the r ...... icines to developing countries
@ast
A lifeline to treatment: the r ...... icines to developing countries
@en
A lifeline to treatment: the r ...... icines to developing countries
@nl
prefLabel
A lifeline to treatment: the r ...... icines to developing countries
@ast
A lifeline to treatment: the r ...... icines to developing countries
@en
A lifeline to treatment: the r ...... icines to developing countries
@nl
P2860
P356
P1476
A lifeline to treatment: the r ...... icines to developing countries
@en
P2093
Ellen Diedrichsen
Suerie Moon
P2860
P2888
P356
10.1186/1758-2652-13-35
P577
2010-09-14T00:00:00Z
P5875
P6179
1009950816